FLORHAM PARK, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate at two upcoming virtual investor conferences in December, including:
- Evercore ISI 3rd Annual HealthCONx Conference
Date: December 1, 2020
Live Presentation Time: 10:55 am ET
- Piper Sandler 32nd Annual Virtual Healthcare Conference
Date: December 2, 2020
Pre-recorded presentation available online
Executive management will also participate in one-on-one meetings during the duration of the conferences.
To access the live webcast and archived recordings for each presentation, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations . Recordings will be available for 30 days following each event.
A bout Phathom
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the Company’s website at www.ph athompharma.com or follow the Company on social media: LinkedIn at www.linkedin.com/company/phathompharma and Twitter @PhathomPharma .
CONT ACTS
Media Contact:
Nick Benedetto
1-877-742-8466
media@phathompharma.com
Investor Contact:
Todd Branning
1-877-742-8466
ir@phathompharma.com
